Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.

Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0000950170-24-007559 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-01-25	2024-01-23	MDGL	Waltermire Robert E.	Senior VP, Chief Pharma Dev	A - Grant	$0.00	+1,419	6,536	+28%	$0
DM	2024-01-25	2024-01-23	MDGL	Waltermire Robert E.	Senior VP, Chief Pharma Dev	A - Grant	$0.00	+3,557	1,419	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-01-23	A	A	1,419	$0.00	6,536	D	—	—
2	Derivative	Stock Option (Right to Buy)	2024-01-23	A	A	2,138	$0.00	2,138	D	$229.00 · — to 2031-01-23	2,138 Common Stock	(F2) The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
3	Derivative	Market Stock Unit	2024-01-23	A	A	1,419	$0.00	1,419	D	— · — to —	1,419 Common Stock	(F3) Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.